Oxcarbazepine
Based on 2 publication(s) in Google Scholar
Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 28721-07-5
- Formula: C15H12N2O2
- Molecular Weight:252.27
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Sodium Channel Blocker Library
HY-L118
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cell Death Library
HY-L162
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Oxcarbazepine
More
Biological Activity
Sodium Channel[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| L02 | IC50 |
>160 μM
Compound: SYSU-20385S
|
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay
|
10.1039/C3MD00397C |
Oxcarbazepine significantly inhibits glioblastoma cell growth and reaches IC50 at therapeutic concentrations. The IC50s of Oxcarbazepine screened with the U87 and T98 cell lines are 12.35 and 9.45 μg/mL,respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human glioma cell lines U-87 MG and T98G
-
Concentration:2.5, 5, 10, 20, and 40 μg/mL
-
Incubation Time:72 hours
-
Result:The growth inhibition for the T98G cell line for each concentration was 17.7±4.1% (2.5 μg/mL), 21.1±3.6% (5 μg/mL), 53.6±14.2% (10 μg/mL), 82.2±2.3% (20 μg/mL), and 85.0±2.3% (40 μg/mL).
The growth inhibition for U-87 MG cell line for each concentration was −1.7±5.1% (0.008 μg/mL), 5.3±2.4% (0.08 μg/mL), 3.5±7.4% (0.8 μg/mL), 0.3±9.2% (16 μg/mL), and −4.2±9.6% (40 μg/mL).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 28721-07-5
-
Appearance Solid
-
Molecular Weight 252.27
-
Formula C15H12N2O2
-
Color White to light yellow
-
SMILES
O=C(N1C2=CC=CC=C2CC(C3=CC=CC=C31)=O)N
-
Synonyms
GP 47680
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Int J Mol Sci
In Vivo Chemical Screening in Zebrafish Embryos Identified FDA-Approved Drugs That Induce Differentiation of Acute Myeloid Leukemia Cells. [Abstract]2024 Jul 16;25(14):7798. PMID: 39063039 -
J Pharmacol Exp Ther
Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs. [Abstract]2025 Oct 31;393(1):103767. PMID: 41406909
Solvent & Solubility
DMSO : 50 mg/mL (198.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ashley M Thomas, et al. Old Friends With New Faces: Are Sodium Channel Blockers the Future of Adjunct Pain Medication Management?J Pain. 2018 Jan;19(1):1-9. [Content Brief]
[2]. Ching-Yi Lee,et al. The effects of antiepileptic drugs on the growth of glioblastoma cell lines. J Neurooncol. 2016 May;127(3):445-53. [Content Brief]
[3]. M Schmutz, et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia. 1994;35 Suppl 5:S47-50. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9640 mL | 19.8200 mL | 39.6401 mL | 99.1002 mL |
| 5 mM | 0.7928 mL | 3.9640 mL | 7.9280 mL | 19.8200 mL | |
| 10 mM | 0.3964 mL | 1.9820 mL | 3.9640 mL | 9.9100 mL | |
| 15 mM | 0.2643 mL | 1.3213 mL | 2.6427 mL | 6.6067 mL | |
| 20 mM | 0.1982 mL | 0.9910 mL | 1.9820 mL | 4.9550 mL | |
| 25 mM | 0.1586 mL | 0.7928 mL | 1.5856 mL | 3.9640 mL | |
| 30 mM | 0.1321 mL | 0.6607 mL | 1.3213 mL | 3.3033 mL | |
| 40 mM | 0.0991 mL | 0.4955 mL | 0.9910 mL | 2.4775 mL | |
| 50 mM | 0.0793 mL | 0.3964 mL | 0.7928 mL | 1.9820 mL | |
| 60 mM | 0.0661 mL | 0.3303 mL | 0.6607 mL | 1.6517 mL | |
| 80 mM | 0.0496 mL | 0.2478 mL | 0.4955 mL | 1.2388 mL | |
| 100 mM | 0.0396 mL | 0.1982 mL | 0.3964 mL | 0.9910 mL |
Oxcarbazepine Related Classifications
HY-B0114 Related Classifications
Powered by Bioz